WT1 and neoplasm: We further exploited the possibilities of this PD-1+ 2D3 based T-cell assay, by evaluating the tumor antigen-presenting capacity of PD-L-disrupted IL-15 DCs loaded with mRNA encoding the full-length WT1 protein.